Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,629 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,170 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients(TOASTIT) | terminated | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | terminated | Early Phase 1 | 2 | Floor Backes, MDOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | terminated | Early Phase 1 | 95 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Nov 22, 2024 | clinicaltrials |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | terminated | Early Phase 1 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy | terminated | Early Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Jun 14, 2022 | clinicaltrials |
| NCT04476251 | E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer | terminated | Early Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 15, 2021 | clinicaltrials |
| NCT03658109 | Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone | terminated | Early Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | terminated | Early Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02411565 | Fermented Wheat Germ Extract in Women With Ovarian Cancer | terminated | Early Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01292733 | Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer(OCEDP) | terminated | Early Phase 1 | 534 | Swedish Medical CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00835679 | Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery | terminated | Early Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00253461 | 11C Topotecan PET Imaging | terminated | Early Phase 1 | 7 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2012 | clinicaltrials |
| NCT00584207 | Radiofrequency Ablation of Uterine Fibroids | terminated | Early Phase 1 | 15 | University of California, DavisOTHER | 1 | Apr 23, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2025source: clinicaltrials